Enovis (NYSE:ENOV) Stock: Insider Angela Lalor Purchases 874 Shares

Enovis Corporation (NYSE:ENOV – Get Free Report) Director Angela Lalor acquired 874 shares of Enovis stock in a transaction on Thursday, November 12th. The stock was purchased at an average cost of $28.04 per share, with a total value of $24,506.96. Following the completion of the transaction, the director directly owned 34,117 shares in the company, valued at $956,640.68. This represents a 2.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Enovis Stock Up 0.6%

NYSE:ENOV traded up $0.17 on Monday, hitting $27.85. The stock had a trading volume of 1,258,195 shares, compared to its average volume of 1,879,055. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. The stock has a market cap of $1.61 billion, a P/E ratio of -3.02 and a beta of 1.31. Enovis Corporation has a 1 year low of $16.70 and a 1 year high of $31.67. The firm’s fifty day simple moving average is $20.71 and its two-hundred day simple moving average is $23.25.

Enovis (NYSE:ENOV – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The firm had revenue of $558.73 million for the quarter, compared to analysts’ expectations of $557.12 million. During the same quarter last year, the firm earned $0.75 EPS. The company’s quarterly revenue was up 1.8% compared to the same quarter last year. Analysts predict that Enovis Corporation will post 3.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. BTIG Research lifted their price target on Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Canaccord Genuity Group cut their price objective on Enovis from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Friday, November 6th. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 2nd. Needham & Company LLC raised their target price on Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Finally, Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.62.

View Our Latest Stock Analysis on ENOV

Institutional Investors Weigh In On Enovis

Hedge funds have recently modified their holdings of the stock. Paradigm Capital Management Inc. NY purchased a new stake in Enovis in the second quarter worth $28,533,000. Bank of America Corp DE bought a new stake in shares of Enovis in the second quarter valued at $11,502,000. Private Management Group Inc. lifted its position in shares of Enovis by 31.3% during the 3rd quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock valued at $32,748,000 after buying an additional 427,347 shares during the last quarter. Man Group plc purchased a new position in shares of Enovis during the 2nd quarter valued at $8,711,000. Finally, Front Street Capital Management Inc. lifted its position in shares of Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after buying an additional 384,124 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

About Enovis

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

Featured Articles

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.